Dealmakers Awards 2024: Deal of the Year (£10m-£50m)

Deal of the Year (£10m-£50m): Sale of Hamilton Waste & Recycling to Biffa (KPMG, MBM Commercial, Chiene + Tait, Rydens, RSM, Burness Paull, Osborne Clarke) Sponsored by Wbg

Hamilton Waste & Recycling is expected to grow in Scotland and beyond after being acquired by Biffa. The deal is set to enable Biffa to expand its capabilities in the construction and demolition sector, and enable more customers to meet carbon reduction commitments. Advisers working on the deal resolved a number of complexities, securing a landmark transaction for recycling and waste management.

Shortlisted

Investment in Antibody Analytics by NorthEdge (Scottish Enterprise, Hill Dickinson, RSM, Claritas, PMSI, Catalysis, Baird, Addleshaw Goddard). The investment will support Antibody Analytics extend its laboratory facility, enabling it to work with more biotech and pharma clients to improve the effect of treatments.

Sale of STATS to Mitsui (BGF, PwC, Blackwoods, AAB, KPMG, Ashurst). Mitsui has the potential to be a great partner for pipeline services firm STATS, with complementary business interests and access to capital.

Investment in Aurora Energy Services by Scottish National Investment Bank (Pinsent Masons, Grant Thornton). The deal saw Aurora’s management team use their own equity to acquire four platform businesses. The bank’s capital was mainly used to fund organic growth to accelerate the roll-out of Aurora’s business model.

Investment in MiAlgae by Equity Gap (SWEN Blue Ocean Ventures, Clay Capital Ventures, Scottish Enterprise, SIS, OCC, DCS, Brodies, WJM, Womble Bond Dickinson). MiAlgae uses whisky wastewater to grow a strain of Omega-3 rich algae. This £13 million investment will enable multi-site growth.

Investment in EnteroBiotix by Scottish National Investment Bank (Thairm Bio, Kineticos Life Sciences, Scottish Enterprise, MBM Commercial, Henderson Loggie, Alacrita, Potter Clarkson). This investment is expected to lead to gut health biopharma firm EnteroBiotix expanding and accelerating its work, broadening its research and development programme, and facilitating new clinical trials to boost the quantity and quality of the data it gathers.